WuXi XDC Cayman Inc. (HKG:2268)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
67.50
-0.50 (-0.74%)
At close: Dec 5, 2025
141.07%
Market Cap 84.64B
Revenue (ttm) 5.58B
Net Income (ttm) 1.45B
Shares Out 1.25B
EPS (ttm) 1.12
PE Ratio 60.36
Forward PE 40.66
Dividend n/a
Ex-Dividend Date n/a
Volume 3,026,461
Average Volume 4,136,979
Open 67.60
Previous Close 68.00
Day's Range 67.40 - 69.25
52-Week Range 24.70 - 85.50
Beta -2.20
RSI 48.91
Earnings Date Nov 18, 2025

About WuXi XDC Cayman

WuXi XDC Cayman Inc., an investment holding company, operates as a contract research, development, and manufacturing organization in China, North America, Europe, and internationally. It engages in the discovery, research, development, and manufacture of the drug substances and drug products of antibody drug conjugates, bioconjugates, monoclonal antibody intermediates, and payload-linkers associated with bioconjugates. It also provides international sales contracting services. The company was founded in 2013 and is headquartered in Wuxi, China.... [Read more]

Sector Healthcare
Founded 2013
Employees 2,041
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 2268
Full Company Profile

Financial Performance

In 2024, WuXi XDC Cayman's revenue was 4.05 billion, an increase of 90.80% compared to the previous year's 2.12 billion. Earnings were 1.07 billion, an increase of 277.24%.

Financial numbers in CNY Financial Statements

News

There is no news available yet.